

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cohort profile: VAScular and Chronic Obstructive Lung disease (VASCOL) - a longitudinal study on morbidity, symptoms, and quality of life among older men in Blekinge County, Sweden

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046473
Article Type:	Cohort profile
Date Submitted by the Author:	05-Nov-2020
Complete List of Authors:	Olsson, Max; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology Engström, Gunnar; Lunds University Faculty of Medicine, Department of Clinical Sciences Malmö Currow, David ; IMPACCT, Faculty of Health, University of Technology Sydney Johnson, Miriam; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull Sandberg, Jacob; Lund University, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology Ekström, Magnus; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology
Keywords:	GERIATRIC MEDICINE, Epidemiology < THORACIC MEDICINE, Cardiac Epidemiology < CARDIOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 **Word count: 2694**
6

7 **Running title:** Morbidity, symptoms, and quality of life among older men
8
9

10 **Cohort profile: VAScular and Chronic Obstructive Lung disease**
11 **(VASCOL) - a longitudinal study on morbidity, symptoms, and quality of**
12 **life among older men in Blekinge County, Sweden.**
13
14
15
16
17

18 Max Olsson, BSPH¹, molsson312@gmail.com; Gunnar Engström, MD, PhD²,
19 gunnar.engstrom@med.lu.se; David C Currow, MPH, PhD³, david.currow@uts.edu.au;
20 Miriam J Johnson, MD, FRCP, MBChB(hons)⁴, miriam.johnson@hyms.ac.uk; Jacob
21 Sandberg, MD¹, jacob.sandberg@gmail.com; Magnus Ekström, MD, PhD¹,
22 pmekstrom@gmail.com.
23
24
25
26
27

28 Affiliations:
29

- 30 1. Lund University, Faculty of Medicine, Department of Clinical Sciences Lund,
31 Respiratory Medicine and Allergology, Lund, Sweden
32
33
- 34 2. Lund University, Faculty of Medicine, Department of Clinical Sciences Malmö,
35 Cardiovascular Epidemiology, Malmö, Sweden
36
37
38
- 39 3. IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, New South
40 Wales, Australia
41
42
43
44
- 45 4. Wolfson Palliative Care Research Centre, Hull York Medical School, University of
46 Hull, Hull, UK
47
48
49
50
51

52 Correspondence to Max Olsson; molsson312@gmail.com
53
54
55
56
57
58
59
60

ABSTRACT

Purpose: Despite data showing breathlessness to be more prevalent in older adults, we have little detail about the severity or multi-dimensional characteristics of breathlessness and other self-reported measures (such as quality of life and other cardiorespiratory-related symptoms) in this group at the population level. We also know little about the relationship between multi-dimensional breathlessness, other symptoms, co-morbidities and future clinical outcomes such as quality of life, hospitalization, and mortality. This paper reports the design and descriptive findings from the first two waves of a longitudinal prospective cohort study in older adults.

Participants: Between 2010-2011, 1900 men in a region in southern Sweden aged 65 years, were invited to attend for VASCOL baseline (Wave 1) assessments which included physiological measurements, blood sampling, and a self-report survey of lifestyle and previous medical conditions. In 2019, follow up postal survey data (Wave 2) were collected with additional self-report measures for breathlessness, other symptoms, and quality of life. At each wave, data are cross-linked with nationwide Swedish registry data of diseases, treatment, hospitalization, and cause of death.

Findings to date: 1302/1900 (68%) of invited men participated in Wave 1, which include 56% of all 65 years old men in the region. 5% reported asthma, 2% chronic obstructive pulmonary disease, 56% hypertension, 10% diabetes, and 19% had airflow limitation. The VASCOL cohort had comparable characteristics to those of similarly aged men in Sweden. By 2019, 109/1302 (8.4%) had died. 907/1193 (76%) of the remainder participated in Wave 2. Internal data completeness of 95% or more was achieved for most Wave 2 measures.

Future plans: A third wave will be conducted within four years, and the cohort will be followed through repeated follow ups planned every fourth year, as well as national registry data of diagnosis, treatments, and cause of death.

Keywords: *Older adults, breathlessness, symptoms, respiratory diseases, cardiovascular diseases, epidemiology.*

STRENGTHS AND LIMITATIONS OF THIS STUDY

- More than half (57%) of all 65 years old men in Blekinge participated in the VASCOL baseline, of which approximately 70 % also participated in the follow up.
- The VASCOL baseline, Wave 1, (n = 1302) collected a wide range of data: physiological measurements, blood samples, survey of lifestyle and self-reported conditions.

- The VASCOL follow up study, Wave 2, (n = 907) included an extensive set of validated self-report instruments of symptoms of cardiorespiratory diseases.
- Cross-linkage of data with national registries allowed prospective study of morbidity, hospitalization, and mortality in this cohort.

INTRODUCTION

Cardiorespiratory diseases, such as ischemic heart disease, heart failure and chronic obstructive pulmonary disease (COPD) are major causes of morbidity and mortality worldwide.^{1,2} They often coexist with, and are worsened by, other conditions leading to poorer outcomes. Multimorbidity increases over the age of 65 years, particularly those with cardiorespiratory diseases.^{3,4,5}

Cardiorespiratory diseases are associated with major adverse health effects including anxiety and depression, poorer quality of sleep and impaired physical capacity.^{6,7} Symptoms of cardiorespiratory diseases includes chest pain, nausea, and fatigue, with the major ‘cardinal’ symptom being *chronic breathlessness*.⁸ Breathlessness is also highly prevalent across the older population,⁹ and the risk of developing breathlessness affecting daily life increases markedly with age.¹⁰ People who are breathless often avoid physical activities,¹¹ many becoming socially isolated.^{8,12} In COPD, breathlessness is a stronger predictor of mortality than the level of airflow limitation.¹³ Breathlessness is also associated with impaired quality of life (QoL), worse physical capacity and higher overall mortality in people with different underlying conditions.^{7,14,8}

Few population-level studies have focused on breathlessness and its relationship with other self-reported outcomes. The BOLD,¹⁵ PLATINO,¹⁶ and ECRHS,¹⁷ studies assessed breathlessness mainly using the unidimensional modified Medical Research Council (mMRC) scale, which thus only assesses the level of exertion required to induce breathlessness, and not the severity of the symptom *per se*.¹² Breathlessness is a multi-dimensional symptom affecting

1
2
3 all domains of a person's life¹⁸ and the intensity of both physical and affective dimensions
4 needs to be included in measurements.^{7,18} For multi-dimensional assessment of breathlessness,
5 the instruments Dyspnoea-12 (D12)¹⁹ and Multidimensional Dyspnea Profile²⁰ (MDP) can be
6 used. Recently, the minimal clinically important difference (MCID) was determined for both
7 D12 and MDP in cardiorespiratory disease.²¹

8
9
10
11
12
13
14
15 Some breathlessness data from older adults at the general population level regarding prevalence
16 and clinical outcomes are published, but details including characteristics, and severity are
17 relatively few. We also know little about other common symptoms and co-morbidities affect
18 clinical outcomes such as QoL, health service utilisation and survival in older adults. To date,
19 no study has assessed the relationship between multi-dimensional breathlessness and clinical
20 outcomes in older adults in the general population.

21
22
23
24
25
26
27
28
29
30 The VAScular and Chronic Obstructive Lung disease study (VASCOL) is an epidemiological,
31 longitudinal, cohort study to describe the relationship between vascular diseases and COPD.
32 Since its beginning in 2010, the scope has broaden to also focus on QoL, self-reported measures
33 of breathlessness and other symptoms of cardiovascular diseases.

34
35
36
37
38
39
40
41 In this paper we present the VASCOL study design, including future longitudinal data
42 collection, describe the characteristics of participants from the first two waves, (Wave 1-
43 baseline; Wave 2 - first follow up).

44 45 46 47 48 49 50 **Study objectives**

51
52
53 The overall objective of the VASCOL study is to evaluate the relationship between life-style
54 variables, morbidity due to cardiorespiratory disease, multi-dimensional breathlessness, other
55 symptoms of cardiovascular diseases, and QoL in a population sample of men aged 65 years
56 on cohort entry. We aim to evaluate:
57
58
59
60

- How baseline factors (diseases, lung function, lifestyle, demographics) predict the outcomes of breathlessness, QoL, diagnosed diseases, hospitalization, and mortality.
- The prevalence, characteristics, and severity of multi-dimensional breathlessness and other symptoms such as anxiety, depression, pain, nausea, and fatigue.
- The relationship between self-reported QoL and symptom burden and functional limitations.
- Contributing causes of breathlessness and other symptoms such as anxiety, depression, pain, nausea, and fatigue.
- How the presence and type of symptoms predicts future diseases.

COHORT DESCRIPTION

The VASCOL study is an ongoing longitudinal epidemiological cohort study in Blekinge, Sweden. Blekinge is a county located in southern Sweden and has a total population of around 160,000, of which approximately 2300 were 65-years old men in 2010-2011. Blekinge geographically covers both urban and rural areas with good public transportations, see Figure 1.

In 2010-2011, 1900 men aged 65 years in Blekinge were invited to a screening campaign of abdominal aortic aneurysm (AAA) at a health centre in the city of Karlshamn.

The men were informed about the VASCOL study and invited to give their informed written consent to participate in the Wave 1 examinations. A self-report survey (demography, lifestyle, and previous diseases) was included with the invitation pack. Blekinge's biggest municipality, Karlskrona, was not included in the screening campaign until 2011, resulting in approximately 80 % (1900/2300) of all 65-years-old men living in Blekinge 2010 - 2011 were invited to participate in the VASCOL study. The inclusion criteria were: men, 65-years old, living in

1
2
3 Blekinge (excluding Karlskrona in 2010), participating in the screening examinations, and
4 willing to give a written consent to participate in the Wave 1 examinations. There were no
5 exclusion criteria based on any conditions. In 2019 a follow up postal survey was sent out to
6 the participants still alive and with a known address (Wave 2).
7
8
9
10
11
12
13
14

15 **Wave 1: baseline data collection**

16
17 At baseline, a clinical visit was performed, and data from the self-report survey collected.
18 Nurses checked for survey data completeness, and those who omitted to bring their survey were
19 also able to complete this during the visit. Physiological measurements and blood sampling
20 were collected according to standard protocols by registered nurses. The blood samples were
21 stored in a biobank for future analysis. Out of the 1900 men attending the screening, 1302
22 (68.5%) participated in the VASCOL baseline study. Normative values for Swedish men in the
23 same age group were also collected from The Public Health Agency of Sweden, National Board
24 of Health and Welfare, and Statistics Sweden.
25
26
27
28
29
30
31
32
33
34
35
36

37 **Wave 2: Follow up survey**

38
39 In 2019, the Blekinge county demographic registers were used to identify all participants who
40 were alive with a known address (n = 1193). A new survey was sent out to all these participants.
41 At Wave 2, 829 of the men replied to the initial survey within two weeks, and additional 78
42 men replied after a reminder, leading to 907/1193 (76%) of men participated in Wave 2. See
43 Figure 2 for detailed information about data collection procedure. The postal survey consisted
44 of questions and validated instruments regarding breathing, other cardiorespiratory-related
45 symptoms, QoL, lifestyle, new medical conditions, and any treatments for breathlessness. Most
46 questions and instruments pertained to the experiences during the last two weeks.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Planned data collection

Repeated waves will be conducted at four yearly intervals, to enable examination of the change in participants' breathlessness, other symptoms and QoL. Wave 3 data collection will be conducted within four years, and the procedure and survey instruments will be similar to the first two waves. Collected data will be cross-linked with nationwide Swedish registry data: Cause of Death Registry, Swedish Prescribed Drug Registry, and National Patient Registry (see table 1).

Table 1. Planned cross linkage with national registries

Data	Source	Timeframe of the data
Inpatient care including diagnoses, date for diagnoses, treatment, date for treatment, and treatment time.	Swedish National Patient Registry for In-patient Care	1987 - today
Outpatient care, diagnosis, date for diagnosis, treatment, date for treatment, and treatment time.	Swedish National Patient Registry for Out-patient Care	2001 - today
Place, date, and cause(s) of death	Causes of Death Registry	Baseline - today
Dispensed prescribed medications	Swedish Prescribed Drug Registry	July 2005 - today

Patient and Public Involvement

The follow up survey was piloted on ten people of similar age to the VASKOL study participants before the final survey was revised and administered. The pilot participants had the opportunity to add areas of research that they thought were relevant. Pilot participants also gave feedback on the layout and length of the survey as well as how the questions were asked. Minor linguistically and layout changes were done to the survey questions to fit the specific study participants.

FINDINGS TO DATE

Baseline characteristics of the VASCOL study are shown in Table 2. The majority of the participants had hypertension (56%), and approximately one fifth had airflow limitation (first second of forced expiration (FEV1) / forced vital capacity (FVC) < 0.7). Only a small proportion had self-reported asthma (5%) or COPD (2%). One tenth (10%) reported diabetes. Also, approximately one tenth of the participants (13%) were everyday smokers, and the majority (54%) were former smokers. Around half of the participants were overweight (52%) and around one third (28%) obese. Participants in the VASCOL cohort had proportions similar to Swedish reference of normative values for similarly aged men concerning everyday smokers, height, FEV1/FVC and civil status. BMI-values, educational level and proportion of former smokers were higher than the reference values.

Overall, the internal data completeness in the follow up was high, with most instruments having 95% completion or more (table 3). Men participating in Wave 2 had an overall better health, healthier lifestyle, and higher education at baseline than those who did not participate in the follow up (table 2). Wave 2 participants had a lower proportion of current smokers, and a lower average number of pack-years. Those providing data for Wave 2, had fewer co-morbidities than those who did not, but who were still alive, other than hypertension which was equally prevalent.

Table 2. Baseline characteristics

Variable	All participants Overall (n = 1302)	Non-missing observations Overall (%)	Participated in follow up (n = 907)	Did not participate in follow (n = 395)	Reference for Swedish 65-year-old men
Self-reported data					
Married	863 (71%)	1210 (93%)	621 (73%)	242 (66%)	61%
Smoking status		1302 (100%)			
Current smoker	168 (13%)		91 (10%)	77 (19%)	13%
Former smoker	707 (54%)		514 (57%)	193 (49%)	36%
Never smoker	427 (33%)		302 (33%)	125 (32%)	51%
Pack-years of smoking	15.1±19.2	1276 (98%)	13.7±17.4	18.4±22.6	
University/college or professional school education	520 (42%)	1218 (93%)	381 (44%)	139 (38%)	25%
Hypertension	725 (56%)	1294 (99%)	507 (56%)	218 (55%)	
Diabetes	132 (10%)	1295(99)	79 (9%)	53 (13%)	
Asthma	71 (5%)	1285(99%)	47 (5%)	24 (6%)	9%*
COPD	29 (2%)	1205 (92%)	13 (1%)	16 (4%)	
Measured data by staff					
Height	179±6.3	1285 (99%)	179±6.1	179±7	178
Body mass index (kg/m2)	28.2±4.1	1275 (98%)	28.1±4.0	28.5±4.4	26*
Underweight, BMI <18.5	1 (0.1%)		1 (0.1%)	0 (0%)	0.6%*
Normal weight, BMI 18.5–24.9	260 (20%)		184 (21%)	76 (20%)	39%*
Overweight, BMI 25–29.9	661 (52%)		470 (53%)	191 (50%)	46%*
Obesity, BMI ≥30	352 (28%)		234 (26%)	118 (31%)	14%*
FEV₁, % of predicted	87.2±15.1	1278 (98%)	88.5±14.7	84.3±15.8	

VC, % of predicted	85.4±13.1	1278 (98%)	86.3±13.0	83.4± 13.1	
FEV₁ / FVC < 0.7	242 (19%)	1295 (99%)	157 (17%)	85 (22%)	18.2%**

Data are presented as mean±SD or frequency (rounded percentage). Normative values were collected from the public available databases of The Public Health Agency of Sweden (www.folkhalsomyndigheten.se), and Statistics Sweden (www.scb.se). The following variables are collected but not included in the table: **Self-reported:** exercise habits, alcohol consumption, tiredness, blood pressure medication, myocardial infarction, stroke, tia, angina pectoris, apnoea, snoring, osteoporosis, fractures, back pain, femur, radius, glaucoma, cataract, intermittent claudication. **Measured by staff:** blood pressure, pulse, weight, waist, swab measure, number of teeth, aortic diameter. **Blood sample:** Hb, HbA1C (% and later mmol), P-cystatin C, p-glucose, PT-GFR(CC estimate), S-CA, S-Na, S-K, S-creatinine, S-total cholesterol, ApoA1, ApoB.

*Reference based on available self-reported data for men 65 years or older

**Reference based on available data for men 40 years or older²²

Table 3. Follow up survey data collected

Measurements and analyses	Description	Non-missing observations, %
Modified Medical Research Council (mMRC) breathlessness scale ²³	Functional impact of breathlessness (yes or no at each item)	97
mMRC-scale	Intensity of functional impact of breathlessness (0-10 at each item)	97
Dyspnoea-12 (D-12) ²⁴	Multidimensional breathlessness	95
Multidimensional Dyspnea Profile (MDP) total ²⁰	Multidimensional breathlessness	77
MDP A1 unpleasantness	Breathing unpleasantness	91
MDP perception score	MDP A1 and five perception descriptors	79
MDP emotional response score	Five emotional descriptors	89
Short form 12 item (version 2) Health survey ¹⁴	Quality of life	98
Edmonton Symptom Assessment System. Revised (ESAS-r) ²⁵	Associated symptoms	98
FACIT-Fatigue ²⁶	Pathological tiredness	98

Hospital Anxiety and Depression Scale (HADS) ²⁷	Anxiety and depression	94
World Health Organization Performance Status 0-4 ²⁸	Performance Status	97
Custom items		
Global impression of change (GIC) ²⁹ in breathlessness since baseline	7 categories from <i>very much better</i> to <i>very much worse</i>	99
Global impression of change (GIC) ²⁹ in health since baseline	7 categories from <i>very much better</i> to <i>very much worse</i>	98
Activities given up because of breathlessness	What activities have the participant giving up due to breathlessness	91
Breathlessness unpleasantness	Likert scale, 4 categories from <i>mild</i> to <i>severe</i> .	93
Breathlessness duration	How many years the participant have experience breathlessness.	89
Proportion of awake time experiencing breathlessness	5 categories from none to whole time awake	91
Experiences temporary worsening breathlessness (how often, how long, when, causative factors).	4-6 categories at each question	94
Self-reported treatments of breathlessness	8 different possible treatments for breathlessness, and free text	89
Smoking status	4 categories (<i>everyday</i> , <i>sometimes</i> , <i>former</i> , and <i>never smoker</i>)	98
Smoking frequency	Years of smoking, and number of cigarettes per day	92
Alcohol use	Amount of wine, beer, and strong spirit a week	84
Quality and duration of sleep	Quality: 5 categories. Duration: 7 categories.	99
Physical activity frequency	4 categories, from daily to never	99
Physical activity intensity	4 categories, from sedentary to intensity	97
Self-reported conditions	19 different possible diseases and conditions	95
Self-reported height and weight now	cm and kg	99
Recall of height and weight at the age of 20	cm and kg	92

Statistical methodology

A detailed statistical analysis plan will be prepared before each analysis. Relevant characteristics for each studies objective will be tabulated and compared using standard descriptive methods. Associations will be evaluated using regression models including logistic regression for categorical outcomes, and linear regression for continuous outcomes. Kaplan-Meier, Cox proportional hazards regression and Fine-Grey regression (accounting for competing events) will be used for time-to-event analyses.

Sample size/Power

The participants in the first follow up of the VASCOL study (Wave 2) covers 45 % of the population of men in the age group (n = 2013) in Blekinge in 2019. Statistical power will be specified for each analysis.

STRENGTHS AND LIMITATIONS

Strengths of the VASCOL study includes that it covers a large proportion of the eligible men in Blekinge. Over half (1302/2300) of all 65-year-old men in Blekinge county participated in the VASCOL baseline. The quality of the data was good, with a high data completeness. The cohort is similar to men aged 65 in Sweden as a whole, which gives confidence regarding generalisability for men, although inherently not so for women or younger men. A limitation is the fact that nearly one-quarters (30%) of the participants did not participate in the follow up (Wave 2). However, all participants in VASCOL baseline can be followed through the national registries, which can give some insight about the participants who did not participate in the follow up (Wave 2). Participants in the follow up study (Wave 2) was overall healthier at baseline than those not participating which might be explained by lower motivation to

1
2
3 participate in studies among those with poorer health or that less healthy participants have
4
5 deceased between the baseline and follow up study.
6

7
8 The VASCOL study is to our knowledge, the most detailed prospective population-based study
9
10 of breathlessness and other symptoms of cardiorespiratory diseases linked to registries with
11
12 key information regarding health service utilisation and survival. Also, there are, to our
13
14 knowledge, few population studies of older men's symptoms and quality of life. The VASCOL
15
16 data are rich and consists of physiological measurements, blood samples, and extensive survey
17
18 data which makes it possible to study many aspects of different symptoms and conditions.
19
20 Sweden has a rich set of health-related registry data that can be cross-linked with the VASCOL
21
22 data, and the variables collected in the VASCOL study can be studied as risk factors for
23
24 outcomes such as morbidity, hospitalization, and mortality. The set of variables of the
25
26 VASCOL data also enables studies of different conditions long term effect on breathlessness
27
28 and other symptoms. The symptom data mostly consist of validated instruments, which enables
29
30 comparison with other studies.
31
32
33

34
35 A limitation of the collected data is that former workplaces was not recorded, and pollution
36
37 from dusty workplaces could possibly be a confounder of breathlessness. We therefore plan to
38
39 include questions about former workplaces in future follow ups. Breathlessness was not
40
41 assessed at baseline so the *Global impression of change (GIC) of breathlessness* was used in
42
43 Wave 2. This introduces the risk of recall bias in studies of changed breathlessness between
44
45 Waves 1 and 2, and an inherently unknown baseline measurement error, but nevertheless is
46
47 accepted as a valid approach. Further, for future VASCOL waves, the repeated self-report
48
49 breathlessness measures will enable longitudinal examination from Wave 2.
50
51
52
53

54
55
56 Cardiorespiratory diseases, as well as breathlessness are common in the older population,^{3,9}
57
58 and we believe that the VASCOL study can add valuable knowledge of the symptoms in the
59
60

1
2
3 population. We will add knowledge regarding which symptoms predict worse clinical
4
5 outcomes to identify people with a higher risk of mortality and morbidity, and as a potential
6
7 therapeutic target.
8
9

10 11 12 **COLLABORATION**

13
14 We welcome researchers from different disciplines and fields for collaboration over the
15
16 collected data from the VASCOL study, including suggested additional data collection.
17
18 Interested researchers should submit a study proposal to the corresponding author. All study
19
20 proposals will be reviewed by the VASCOL research group. All additional objectives not
21
22 included in this paper must also be approved by the Sweden's national ethical review board.
23
24
25
26
27

28 **ACKNOWLEDGEMENTS**

29
30 We thank associate professor Kerstin Ström who initiated and led the VASKOL baseline study,
31
32 the nurses and staff that performed the assessments, and all participants who contributed to this
33
34 research.
35
36
37
38

39 **FURTHER DETAILS**

40
41
42 **Author Contributions:** Conception and design: ME; Data collection: MO, ME; Analysis:
43
44 MO, ME; Interpretation: All authors; First draft: MO, ME; Revisions and acceptance of the
45
46 version to publish: All authors.
47
48

49
50 **Funding:** The VASCOL baseline study was funded by the Research Council of Blekinge. MO
51
52 and ME was supported by an unrestricted grant from the Swedish Research Council (reference
53
54 number: 2019-02081).
55
56

57 **Competing Interests Statement:** None declared
58
59
60

1
2
3 **Ethics approval:** The baseline study was approved by the regional ethical review board at
4
5 Lund University (reference number: 2008/676). The first follow up study and the registry
6
7 data cross linkage was approved by the national ethical review board (reference number:
8
9 2019-00134).

10
11
12
13
14 **Data sharing statement:** The VASCOL research group will consider requests for using de-
15
16 identified data from the VASCOL study by external collaborators. Also, all requests must be
17
18 approved by the Sweden's national ethical review board.
19
20
21

22 23 24 **Licence statement**

25 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work
26
27 (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
28
29 contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY
30
31 licence shall apply, and/or iii) in accordance with the terms applicable for US Federal
32
33 Government officers or employees acting as part of their official duties; on a worldwide,
34
35 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and
36
37 where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the
38
39 Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).

40
41
42
43
44 The Submitting Author accepts and understands that any supply made under these terms is
45
46 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
47
48 employer or a postgraduate student of an affiliated institution which is paying any applicable
49
50 article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes
51
52 to make the Work available on an Open Access basis (and intends to pay the relevant APC), the
53
54 terms of reuse of such Open Access shall be governed by a Creative Commons licence – details
55
56 of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our
57
58 licence referred to above.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol* 2017;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052 [published Online First: 2017/05/22]
2. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. *Clin Geriatr Med* 2009;25(4):563-77, vii. doi: 10.1016/j.cger.2009.07.007 [published Online First: 2009/12/01]
3. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]
4. Carter P, Lagan J, Fortune C, et al. Association of Cardiovascular Disease With Respiratory Disease. *J Am Coll Cardiol* 2019;73(17):2166-77. doi: 10.1016/j.jacc.2018.11.063 [published Online First: 2019/03/09]
5. Sandberg J, Ekstrom M, Borjesson M, et al. Underlying contributing conditions to breathlessness among middle-aged individuals in the general population: a cross-sectional study. *BMJ Open Respir Res* 2020;7(1) doi: 10.1136/bmjresp-2020-000643 [published Online First: 2020/09/27]
6. Zambroski CH, Moser DK, Bhat G, et al. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. *Eur J Cardiovasc Nurs* 2005;4(3):198-206. doi: 10.1016/j.ejcnurse.2005.03.010 [published Online First: 2005/05/27]
7. Laviolette L, Laveneziana P, Faculty ERSRS. Dyspnoea: a multidimensional and multidisciplinary approach. *Eur Respir J* 2014;43(6):1750-62. doi: 10.1183/09031936.00092613 [published Online First: 2014/02/15]
8. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *Eur Respir J* 2017;49(5) doi: 10.1183/13993003.02277-2016 [published Online First: 2017/05/27]
9. Smith AK, Currow DC, Abernethy AP, et al. Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. *J Am Geriatr Soc* 2016;64(10):2035-41. doi: 10.1111/jgs.14313 [published Online First: 2016/10/21]
10. Gronseth R, Vollmer WM, Hardie JA, et al. Predictors of dyspnoea prevalence: results from the BOLD study. *Eur Respir J* 2014;43(6):1610-20. doi: 10.1183/09031936.00036813 [published Online First: 2013/11/02]
11. Kochovska S, Chang S, Morgan DD, et al. Activities Forgone because of Chronic Breathlessness: A Cross-Sectional Population Prevalence Study. *Palliative Medicine Reports* 2020;1(1):166-70. doi: 10.1089/pmr.2020.0083
12. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med* 2012;185(4):435-52. doi: 10.1164/rccm.201111-2042ST [published Online First: 2012/02/18]
13. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. *Chest* 2002;121(5):1434-40. doi: 10.1378/chest.121.5.1434 [published Online First: 2002/05/15]
14. Currow DC, Dal Grande E, Ferreira D, et al. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax* 2017;72(12):1151-53. doi: 10.1136/thoraxjnl-2016-209908 [published Online First: 2017/03/31]

15. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4 [published Online First: 2007/09/04]
16. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *Lancet* 2005;366(9500):1875-81. doi: 10.1016/S0140-6736(05)67632-5 [published Online First: 2005/11/29]
17. Heinrich J, Richter K, Frye C, et al. [European Community Respiratory Health Survey in Adults (ECRHS)]. *Pneumologie* 2002;56(5):297-303. doi: 10.1055/s-2002-30699 [published Online First: 2002/06/29]
18. Hutchinson A, Barclay-Klingling N, Galvin K, et al. Living with breathlessness: a systematic literature review and qualitative synthesis. *Eur Respir J* 2018;51(2) doi: 10.1183/13993003.01477-2017 [published Online First: 2018/02/23]
19. Sundh J, Ekstrom M. Dyspnoea-12: a translation and linguistic validation study in a Swedish setting. *BMJ Open* 2017;7(5):e014490. doi: 10.1136/bmjopen-2016-014490 [published Online First: 2017/06/09]
20. Ekstrom M, Bornefalk H, Skold M, et al. Validation of the Swedish Multidimensional Dyspnea Profile (MDP) in outpatients with cardiorespiratory disease. *BMJ Open Respir Res* 2019;6(1):e000381. doi: 10.1136/bmjresp-2018-000381 [published Online First: 2019/11/05]
21. Ekstrom MP, Bornefalk H, Skold CM, et al. Minimal Clinically Important Differences and Feasibility of Dyspnea-12 and the Multidimensional Dyspnea Profile in Cardiorespiratory Disease. *J Pain Symptom Manage* 2020 doi: 10.1016/j.jpainsymman.2020.05.028 [published Online First: 2020/06/09]
22. Danielsson P, Olafsdottir IS, Benediktsdottir B, et al. The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden--the Burden of Obstructive Lung Disease (BOLD) study: cross-sectional population-based study. *Clin Respir J* 2012;6(2):120-7. doi: 10.1111/j.1752-699X.2011.00257.x [published Online First: 2011/06/10]
23. Ekstrom M, Chang S, Johnson MJ, et al. Low agreement between mMRC rated by patients and clinicians: implications for practice. *Eur Respir J* 2019;54(6) doi: 10.1183/13993003.01517-2019 [published Online First: 2019/10/19]
24. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. *Thorax* 2010;65(1):21-26. doi: 10.1136/thx.2009.118521
25. Hannon B, Dyck M, Pope A, et al. Modified Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer. *J Pain Symptom Manage* 2015;49(5):945-52. doi: 10.1016/j.jpainsymman.2014.10.013 [published Online First: 2014/12/20]
26. Al-shair K, Muellerova H, Yorke J, et al. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. *Health Qual Life Outcomes* 2012;10:100. doi: 10.1186/1477-7525-10-100 [published Online First: 2012/08/24]
27. Nowak C, Sievi NA, Clarenbach CF, et al. Accuracy of the Hospital Anxiety and Depression Scale for identifying depression in chronic obstructive pulmonary disease patients. *Pulm Med* 2014;2014:973858. doi: 10.1155/2014/973858 [published Online First: 2014/12/31]
28. Young J, Badgery-Parker T, Dobbins T, et al. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. *J Pain Symptom Manage* 2015;49(2):258-64. doi: 10.1016/j.jpainsymman.2014.06.006 [published Online First: 2014/07/06]
29. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. *J Manipulative Physiol Ther* 2004;27(1):26-35. doi: 10.1016/j.jmpt.2003.11.003 [published Online First: 2004/01/24]

FIGURE LEGENDS

Figure 1- Location of Blekinge in Sweden, Blekinge's municipalities and main cities.

Figure 2 - Flow chart of the recruitment for the VASCOL study

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1 - Location of Blekinge in Sweden, Blekinge's municipalities and main cities.

57x46mm (300 x 300 DPI)




Figure 2 - Flow chart of the recruitment for the VASCOL study

145x206mm (300 x 300 DPI)

BMJ Open

Cohort profile: VAScular and Chronic Obstructive Lung disease (VASCOL) - a longitudinal study on morbidity, symptoms, and quality of life among older men in Blekinge County, Sweden

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046473.R1
Article Type:	Cohort profile
Date Submitted by the Author:	25-May-2021
Complete List of Authors:	Olsson, Max; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology Engström, Gunnar; Lunds University Faculty of Medicine, Department of Clinical Sciences Malmö Currow, David ; IMPACCT, Faculty of Health, University of Technology Sydney Johnson, Miriam; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull Sandberg, Jacob; Lund University, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology Ekström, Magnus; Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology
Primary Subject Heading:	Geriatric medicine
Secondary Subject Heading:	Epidemiology, Public health, Respiratory medicine, Cardiovascular medicine
Keywords:	GERIATRIC MEDICINE, Epidemiology < THORACIC MEDICINE, Cardiac Epidemiology < CARDIOLOGY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5 **Word count: 2785**

6 **Running title:** Morbidity, symptoms, and quality of life among older men
7
8
9

10 **Cohort profile: VAScular and Chronic Obstructive Lung disease**
11 **(VASCOL) - a longitudinal study on morbidity, symptoms, and quality of**
12 **life among older men in Blekinge County, Sweden.**
13
14
15
16
17

18 Max Olsson, BSPH¹, molsson312@gmail.com; Gunnar Engström, MD, PhD²,
19 gunnar.engstrom@med.lu.se; David C Currow, MPH, PhD³, david.currow@uts.edu.au;
20 Miriam J Johnson, MD, FRCP, MBChB(hons)⁴, miriam.johnson@hyms.ac.uk; Jacob
21 Sandberg, MD¹, jacob.sandberg@gmail.com; Magnus Ekström, MD, PhD¹,
22 pmekstrom@gmail.com.
23
24
25
26
27

28 Affiliations:
29

- 30 1. Lund University, Faculty of Medicine, Department of Clinical Sciences Lund,
31 Respiratory Medicine and Allergology, Lund, Sweden
32
33
- 34 2. Lund University, Faculty of Medicine, Department of Clinical Sciences Malmö,
35 Cardiovascular Epidemiology, Malmö, Sweden
36
37
- 38 3. IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, New South
39 Wales, Australia
40
41
- 42 4. Wolfson Palliative Care Research Centre, Hull York Medical School, University of
43 Hull, Hull, UK
44
45
46
47
48
49
50
51

52 Correspondence to Max Olsson, Dept of Clinical Sciences, Division of Respiratory Medicine
53 and Allergology, Lund University, SE-221 84 Lund, Sweden. E-mail:
54 molsson312@gmail.com, telephone: +46708688587, fax: +46 455-802 50.
55
56
57
58
59
60

ABSTRACT

Purpose: Despite data showing breathlessness to be more prevalent in older adults, we have little detail about the severity or multi-dimensional characteristics of breathlessness and other self-reported measures (such as quality of life and other cardiorespiratory-related symptoms) in this group at the population level. We also know little about the relationship between multi-dimensional breathlessness, other symptoms, co-morbidities and future clinical outcomes such as quality of life, hospitalization, and mortality. This paper reports the design and descriptive findings from the first two waves of a longitudinal prospective cohort study in older adults.

Participants: Between 2010-2011, 1900 men in a region in southern Sweden aged 65 years, were invited to attend for VASCOL baseline (Wave 1) assessments which included physiological measurements, blood sampling, and a self-report survey of lifestyle and previous medical conditions. In 2019, follow up postal survey data (Wave 2) were collected with additional self-report measures for breathlessness, other symptoms, and quality of life. At each wave, data are cross-linked with nationwide Swedish registry data of diseases, treatment, hospitalization, and cause of death.

Findings to date: 1302/1900 (68%) of invited men participated in Wave 1, which include 56% of all 65 years old men in the region. 5% reported asthma, 2% chronic obstructive pulmonary disease, 56% hypertension, 10% diabetes, and 19% had airflow limitation. The VASCOL cohort had comparable characteristics to those of similarly aged men in Sweden. By 2019, 109/1302 (8.4%) had died. 907/1193 (76%) of the remainder participated in Wave 2. Internal data completeness of 95% or more was achieved for most Wave 2 measures.

Future plans: A third wave will be conducted within four years, and the cohort will be followed through repeated follow ups planned every fourth year, as well as national registry data of diagnosis, treatments, and cause of death.

Keywords: *Older adults, breathlessness, symptoms, respiratory diseases, cardiovascular diseases, epidemiology.*

STRENGTHS AND LIMITATIONS OF THIS STUDY

- More than half (57%) of all 65 years old men in Blekinge participated in the VASCOL baseline, of which approximately 70 % also participated in the follow up.

- The VASCOL baseline, Wave 1, (n = 1302) collected a wide range of data: physiological measurements, blood samples, survey of lifestyle and self-reported conditions.
- The VASCOL follow up study, Wave 2, (n = 907) included an extensive set of validated self-report instruments of symptoms of cardiorespiratory diseases.
- Cross-linkage of data with national registries allowed prospective study of morbidity, hospitalization, and mortality in this cohort.

INTRODUCTION

Cardiorespiratory diseases, such as ischemic heart disease, heart failure and chronic obstructive pulmonary disease (COPD) are major causes of morbidity and mortality worldwide.^{1,2} They often coexist with, and are worsened by, other conditions leading to poorer outcomes. Multimorbidity increases over the age of 65 years, particularly those with cardiorespiratory diseases.^{3,4,5}

Cardiorespiratory diseases are associated with major adverse health effects including anxiety and depression, poorer quality of sleep and impaired physical capacity.^{6,7} Symptoms of cardiorespiratory diseases includes chest pain, nausea, and fatigue, with the major ‘cardinal’ symptom being *chronic breathlessness*.⁸ Breathlessness is also highly prevalent across the older population,⁹ and the risk of developing breathlessness affecting daily life increases markedly with age.¹⁰ People who are breathless often avoid physical activities,¹¹ many becoming socially isolated.^{8,12} In COPD, breathlessness is a stronger predictor of mortality than the level of airflow limitation.¹³ Breathlessness is also associated with impaired quality of life (QoL), worse physical capacity and higher overall mortality in people with different underlying conditions.^{7,14,8}

Few population-level studies have focused on breathlessness and its relationship with other self-reported outcomes. The BOLD,¹⁵ PLATINO,¹⁶ and ECRHS,¹⁷ studies assessed breathlessness mainly using the unidimensional modified Medical Research Council (mMRC)

1
2
3 scale, which thus only assesses the level of exertion required to induce breathlessness, and not
4
5 the severity of the symptom *per se*.¹² Breathlessness is a multi-dimensional symptom affecting
6
7 all domains of a person's life¹⁸ and the intensity of both physical and affective dimensions
8
9 needs to be included in measurements.^{7, 18} For multi-dimensional assessment of breathlessness,
10
11 the instruments Dyspnoea-12 (D12)¹⁹ and Multidimensional Dyspnea Profile²⁰ (MDP) can be
12
13 used. Recently, the minimal clinically important difference (MCID) was determined for both
14
15 D12 and MDP in cardiorespiratory disease.²¹
16
17

18
19
20 Some breathlessness data from older adults at the general population level regarding prevalence
21
22 and clinical outcomes are published, but details including characteristics, and severity are
23
24 relatively few. We also know little about other common symptoms and co-morbidities affect
25
26 clinical outcomes such as QoL, health service utilisation and survival in older adults. To date,
27
28 no study has assessed the relationship between multi-dimensional breathlessness and clinical
29
30 outcomes in older adults in the general population.
31
32

33
34 The VAScular and Chronic Obstructive Lung disease study (VASCOL) is an epidemiological,
35
36 longitudinal, cohort study to describe the relationship between vascular diseases and COPD.
37
38 Since its beginning in 2010, the scope has broaden to also focus on QoL, self-reported measures
39
40 of breathlessness and other symptoms of cardiovascular diseases.
41
42

43
44
45 In this paper we present the VASCOL study design, including future longitudinal data
46
47 collection, describe the characteristics of participants from the first two waves, (Wave 1-
48
49 baseline; Wave 2 - first follow up).
50
51

52 53 54 55 **Study objectives**

56
57 The overall objective of the VASCOL study is to evaluate the relationship between life-style
58
59 variables, morbidity due to cardiorespiratory disease, multi-dimensional breathlessness, other
60

1
2
3 symptoms of cardiovascular diseases, and QoL in a population sample of men aged 65 years
4
5 on cohort entry. We aim to evaluate:

- 6
7
8 • How baseline factors (diseases, lung function, lifestyle, demographics) predict the
9
10 outcomes of breathlessness, QoL, diagnosed diseases, hospitalization, and mortality.
- 11
12 • The prevalence, characteristics, and severity of multi-dimensional breathlessness and
13
14 other symptoms such as anxiety, depression, pain, nausea, and fatigue.
- 15
16 • The relationship between self-reported QoL and symptom burden and functional
17
18 limitations.
- 19
20 • Contributing causes of breathlessness and other symptoms such as anxiety, depression,
21
22 pain, nausea, and fatigue.
- 23
24 • How the presence and type of symptoms predicts future diseases.
- 25
26
27
28
29
30
31

32 **COHORT DESCRIPTION**

33
34
35 The VASCOL study is an ongoing longitudinal epidemiological cohort study in Blekinge,
36
37 Sweden. Blekinge is a county located in southern Sweden and has a total population of around
38
39 160,000, of which approximately 2300 were 65-years old men in 2010-2011. Blekinge
40
41 geographically covers both urban and rural areas with good public transportations, see Figure
42
43
44
45 1.

46
47
48 In 2010-2011, 1900 men aged 65 years in Blekinge were invited to a screening campaign of
49
50 abdominal aortic aneurysm (AAA) at a health centre in the city of Karlshamn.

51
52
53 The men were informed about the VASCOL study and invited to give their informed written
54
55 consent to participate in the Wave 1 examinations. A self-report survey (demography, lifestyle,
56
57 and previous diseases) was included with the invitation pack. Blekinge's biggest municipality,
58
59 Karlskrona, was not included in the screening campaign until 2011, resulting in approximately
60

1
2
3 80 % (1900/2300) of all 65-years-old men living in Blekinge 2010 - 2011 were invited to
4 participate in the VASCOL study. The inclusion criteria were: men, 65-years old, living in
5 Blekinge (excluding Karlskrona in 2010), participating in the screening examinations, and
6 willing to give a written consent to participate in the Wave 1 examinations. There were no
7 exclusion criteria based on any conditions. In 2019 a follow up postal survey was sent out to
8 the participants still alive and with a known address (Wave 2).
9
10
11
12
13
14
15
16
17
18

19 **Wave 1: baseline data collection**

20
21
22 At baseline, a clinical visit was performed, and data from the self-report survey collected.
23 Nurses checked for survey data completeness, and those who omitted to bring their survey were
24 also able to complete this during the visit. Physiological measurements and blood sampling
25 were collected according to standard protocols by registered nurses. The blood samples were
26 stored in a biobank for future analysis. Out of the 1900 men attending the screening, 1302
27 (68.5%) participated in the VASCOL baseline study. Normative values for Swedish men in the
28 same age group were also collected from The Public Health Agency of Sweden, National Board
29 of Health and Welfare, and Statistics Sweden.
30
31
32
33
34
35
36
37
38
39
40

41 **Wave 2: Follow up survey**

42
43 In 2019, the Blekinge county demographic registers were used to identify all participants who
44 were alive with a known address (n = 1193). A new survey was sent out to all these participants.
45
46 At Wave 2, 829 of the men replied to the initial survey within two weeks, and additional 78
47 men replied after a reminder, leading to 907/1193 (76%) of men participated in Wave 2. See
48 Figure 2 for detailed information about data collection procedure. The postal survey consisted
49 of questions and validated instruments regarding breathing, other cardiorespiratory-related
50 symptoms, QoL, lifestyle, new medical conditions, and any treatments for breathlessness. Most
51 questions and instruments pertained to the experiences during the last two weeks.
52
53
54
55
56
57
58
59
60

Planned data collection

Repeated waves will be conducted at four yearly intervals, to enable examination of the change in participants' breathlessness, other symptoms and QoL. Wave 3 data collection will be conducted within four years, and the procedure and survey instruments will be similar to the first two waves. To broaden the VASCOL study and reach a bigger sample size, future data collections should also invite women to participate. Collected data will be cross-linked with nationwide Swedish registry data: Cause of Death Registry, Swedish Prescribed Drug Registry, and National Patient Registry (see table 1). The Swedish registry databases have high coverage and completeness, but are limited in that they are not including any (or very limited) physiologic variables and no symptoms or other patient reported outcomes. The VASCOL study and the registry databases will therefore complete each other.

Table 1. Planned cross linkage with national registries

Data	Source	Timeframe of the data
Inpatient care including diagnoses, date for diagnoses, treatment, date for treatment, and treatment time.	Swedish National Patient Registry for In-patient Care	1987 - today
Outpatient care, diagnosis, date for diagnosis, treatment, date for treatment, and treatment time.	Swedish National Patient Registry for Out-patient Care	2001 - today
Place, date, and cause(s) of death	Causes of Death Registry	Baseline - today
Dispensed prescribed medications	Swedish Prescribed Drug Registry	July 2005 - today

Patient and Public Involvement

1
2
3 The follow up survey was piloted on ten people of similar age to the VASKOL study
4
5 participants before the final survey was revised and administered. The pilot participants had
6
7 the opportunity to add areas of research that they thought were relevant. Pilot participants
8
9 also gave feedback on the layout and length of the survey as well as how the questions were
10
11 asked. Minor linguistically and layout changes were done to the survey questions to fit the
12
13 specific study participants.
14
15

16 17 **FINDINGS TO DATE**

18
19
20 Baseline characteristics of the VASCOL study are shown in Table 2. The majority of the
21
22 participants had hypertension (56%), and approximately one fifth had airflow limitation (first
23
24 second of forced expiration (FEV1) / forced vital capacity (FVC) < 0.7). Only a small
25
26 proportion had self-reported asthma (5%) or COPD (2%). One tenth (10%) reported diabetes.
27
28 Also, approximately one tenth of the participants (13%) were everyday smokers, and the
29
30 majority (54%) were former smokers. Around half of the participants were overweight (52%)
31
32 and around one third (28%) obese. Participants in the VASCOL cohort had proportions similar
33
34 to Swedish reference of normative values for similarly aged men concerning everyday smokers,
35
36 height, FEV1/FVC and civil status. BMI-values, educational level and proportion of former
37
38 smokers were higher than the reference values.
39
40
41

42
43 Overall, the internal data completeness in the follow up was high, with most instruments
44
45 having 95% completion or more (table 3). Men participating in Wave 2 had an overall better
46
47 health, healthier lifestyle, and higher education at baseline than those who did not participate
48
49 in the follow up (table 2). Wave 2 participants had a lower proportion of current smokers, and
50
51 a lower average number of pack-years. Those providing data for Wave 2, had fewer co-
52
53 morbidities than those who did not, but who were still alive, other than hypertension which
54
55 was equally prevalent.
56
57
58
59
60

Variable	All participants Overall (n = 1302)	Non-missing observations Overall (%)	Participated in follow up (n = 907)	Did not participate in follow (n = 395)	Reference for Swedish 65-year-old men
Self-reported data					
Married	863 (71%)	1210 (93%)	621 (73%)	242 (66%)	61%
Smoking status		1302 (100%)			
Current smoker	168 (13%)		91 (10%)	77 (19%)	13%
Former smoker	707 (54%)		514 (57%)	193 (49%)	36%
Never smoker	427 (33%)		302 (33%)	125 (32%)	51%
Pack-years of smoking	15.1±19.2	1276 (98%)	13.7±17.4	18.4±22.6	
University/college or professional school education	520 (42%)	1218 (93%)	381 (44%)	139 (38%)	25%
Hypertension	725 (56%)	1294 (99%)	507 (56%)	218 (55%)	
Diabetes	132 (10%)	1295(99)	79 (9%)	53 (13%)	
Asthma	71 (5%)	1285(99%)	47 (5%)	24 (6%)	9%*
COPD	29 (2%)	1205 (92%)	13 (1%)	16 (4%)	
Measured data by staff					
Height	179±6.3	1285 (99%)	179±6.1	179±7	178
Body mass index (kg/m²)	28.2±4.1	1275 (98%)	28.1±4.0	28.5±4.4	26*
Underweight, BMI <18.5	1 (0.1%)		1 (0.1%)	0 (0%)	0.6%*
Normal weight, BMI 18.5–24.9	260 (20%)		184 (21%)	76 (20%)	39%*
Overweight, BMI 25–29.9	661 (52%)		470 (53%)	191 (50%)	46%*
Obesity, BMI ≥30	352 (28%)		234 (26%)	118 (31%)	14%*

Table 2. Baseline characteristics

FEV₁, % of predicted	87.2±15.1	1278 (98%)	88.5±14.7	84.3±15.8	
VC, % of predicted	85.4±13.1	1278 (98%)	86.3±13.0	83.4± 13.1	
FEV₁ / FVC < 0.7	242 (19%)	1295 (99%)	157 (17%)	85 (22%)	18.2%**

Data are presented as mean±SD or frequency (rounded percentage). Normative values were collected from the public available databases of The Public Health Agency of Sweden (www.folkhalsomyndigheten.se), and Statistics Sweden (www.scb.se). The following variables are collected but not included in the table: **Self-reported:** exercise habits, alcohol consumption, tiredness, blood pressure medication, myocardial infarction, stroke, tia, angina pectoris, apnoea, snoring, osteoporosis, fractures, back pain, femur, radius, glaucoma, cataract, intermittent claudication. **Measured by staff:** blood pressure, pulse, weight, waist, swab measure, number of teeth, aortic diameter. **Blood sample:** Hb, HbA1C (% and later mmol), P-cystatin C, p-glucose, PT-GFR(CC estimate), S-CA, S-Na, S-K, S-creatinine, S-total cholesterol, ApoA1, ApoB.

*Reference based on available self-reported data for men 65 years or older

**Reference based on available data for men 40 years or older²²

Table 3. Follow up survey data collected

Measurements and analyses	Description	Non-missing observations, %
Modified Medical Research Council (mMRC) breathlessness scale ²³	Functional impact of breathlessness (yes or no at each item)	97
mMRC-scale	Intensity of functional impact of breathlessness (0-10 at each item)	97
Dyspnoea-12 (D-12) ²⁴	Multidimensional breathlessness	95
Multidimensional Dyspnea Profile (MDP) total ²⁰	Multidimensional breathlessness	77
MDP A1 unpleasantness	Breathing unpleasantness	91
MDP perception score	MDP A1 and five perception descriptors	79
MDP emotional response score	Five emotional descriptors	89
Short form 12 item (version 2) Health survey ¹⁴	Quality of life	98
Edmonton Symptom Assessment System. Revised (ESAS-r) ²⁵	Associated symptoms	98

FACIT-Fatigue ²⁶	Pathological tiredness	98
Hospital Anxiety and Depression Scale (HADS) ²⁷	Anxiety and depression	94
World Health Organization Performance Status 0-4 ²⁸	Performance Status	97
Custom items		
Global impression of change (GIC) ²⁹ in breathlessness since baseline	7 categories from <i>very much better</i> to <i>very much worse</i>	99
Global impression of change (GIC) ²⁹ in health since baseline	7 categories from <i>very much better</i> to <i>very much worse</i>	98
Activities given up because of breathlessness	What activities have the participant giving up due to breathlessness	91
Breathlessness unpleasantness	Likert scale, 4 categories from <i>mild</i> to <i>severe</i> .	93
Breathlessness duration	How many years the participant have experience breathlessness.	89
Proportion of awake time experiencing breathlessness	5 categories from none to whole time awake	91
Experiences temporary worsening breathlessness (how often, how long, when, causative factors).	4-6 categories at each question	94
Self-reported treatments of breathlessness	8 different possible treatments for breathlessness, and free text	89
Smoking status	4 categories (<i>everyday</i> , <i>sometimes</i> , <i>former</i> , and <i>never smoker</i>)	98
Smoking frequency	Years of smoking, and number of cigarettes per day	92
Alcohol use	Amount of wine, beer, and strong spirit a week	84
Quality and duration of sleep	Quality: 5 categories. Duration: 7 categories.	99
Physical activity frequency	4 categories, from daily to never	99
Physical activity intensity	4 categories, from sedentary to intensity	97
Self-reported conditions	19 different possible diseases and conditions	95
Self-reported height and weight now	cm and kg	99

Recall of height and weight at the age of 20	cm and kg	92
--	-----------	----

Statistical methodology

A detailed statistical analysis plan will be prepared before each analysis. Relevant characteristics for each studies objective will be tabulated and compared using standard descriptive methods. Associations will be evaluated using regression models including logistic regression for categorical outcomes, and linear regression for continuous outcomes. Kaplan-Meier, Cox proportional hazards regression and Fine-Grey regression (accounting for competing events) will be used for time-to-event analyses.

Sample size/Power

The participants in the first follow up of the VASCOL study (Wave 2) covers 45 % of the population of men in the age group (n = 2013) in Blekinge in 2019. Statistical power will be specified for each analysis.

STRENGTHS AND LIMITATIONS

Strengths of the VASCOL study includes that it covers a large proportion of the eligible men in Blekinge. Over half (1302/2300) of all 65-year-old men in Blekinge county participated in the VASCOL baseline. The quality of the data was good, with a high data completeness. The cohort is similar to men aged 65 in Sweden as a whole, which gives confidence regarding generalisability for men. However, a limitation is that we cannot generalise for women or younger men and future data collections should therefore include these groups. A limitation is the fact that nearly one-quarters (30%) of the participants did not participate in the follow up (Wave 2). However, all participants in VASCOL baseline can be followed through the national registries, which can give some insight about the participants who did not participate in the

1
2
3 follow up (Wave 2). Participants in the follow up study (Wave 2) was overall healthier at
4 baseline than those not participating which might be explained by lower motivation to
5 participate in studies among those with poorer health or that less healthy participants have
6
7
8
9
10 deceased between the baseline and follow up study.

11
12 The VASCOL study is to our knowledge, the most detailed prospective population-based study
13 of breathlessness and other symptoms of cardiorespiratory diseases linked to registries with
14 key information regarding health service utilisation and survival. Also, there are, to our
15 knowledge, few population studies of older men's symptoms and quality of life. The VASCOL
16 data are rich and consists of physiological measurements, blood samples, and extensive survey
17 data which makes it possible to study many aspects of different symptoms and conditions.
18
19 Sweden has a rich set of health-related registry data that can be cross-linked with the VASCOL
20 data, and the variables collected in the VASCOL study can be studied as risk factors for
21 outcomes such as morbidity, hospitalization, and mortality. The set of variables of the
22 VASCOL data also enables studies of different conditions long term effect on breathlessness
23 and other symptoms. The symptom data mostly consist of validated instruments, which enables
24 comparison with other studies.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 A limitation of the collected data is that former workplaces was not recorded, and pollution
41 from dusty workplaces could possibly be a confounder of breathlessness. Also, cough was not
42 measured, which is a common symptom of COPD. We therefore plan to include questions
43 about former workplaces and cough in future follow ups. Breathlessness was not assessed at
44 baseline so the *Global impression of change (GIC) of breathlessness* was used in Wave 2. This
45 introduces the risk of recall bias in studies of changed breathlessness between Waves 1 and 2,
46 and an inherently unknown baseline measurement error, but nevertheless is accepted as a valid
47 approach. Further, for future VASCOL waves, the repeated self-report breathlessness measures
48 will enable longitudinal examination from Wave 2.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 Cardiorespiratory diseases, as well as breathlessness are common in the older population,^{3,9}
6
7 and we believe that the VASCOL study can add valuable knowledge of the symptoms in the
8
9 population. We will add knowledge regarding which symptoms predict worse clinical
10
11 outcomes to identify people with a higher risk of mortality and morbidity, and as a potential
12
13 therapeutic target.
14
15
16
17
18

19 **COLLABORATION**

20
21 We welcome researchers from different disciplines and fields for collaboration over the
22
23 collected data from the VASCOL study, including suggested additional data collection.
24
25 Interested researchers should submit a study proposal to the corresponding author. All study
26
27 proposals will be reviewed by the VASCOL research group. All additional objectives not
28
29 included in this paper must also be approved by the Sweden's national ethical review board.
30
31
32
33
34

35 **ACKNOWLEDGEMENTS**

36
37 We thank associate professor Kerstin Ström who initiated and led the VASKOL baseline study,
38
39 the nurses and staff that performed the assessments, and all participants who contributed to this
40
41 research.
42
43
44
45

46 **FURTHER DETAILS**

47
48 **Contributors:** ME was responsible for the conceptualisation of the wave 2 study and will take
49
50 the role as principal investigator. Kerstin Ström was responsible for the wave 1 data collection.
51
52 ME and MO conducted wave 2 data collection and will collect the data for wave 3 as well as
53
54 cross-linking data with national registries. MO, ME wrote the first draft of this cohort profile.
55
56 GE, DC, MJ, and JS contributed with their research experience and medical knowledge in
57
58
59
60

1
2
3 interpretation of the findings, review, and revision of the manuscript draft. All authors
4
5 approved the final version.
6
7

8 **Funding:** The VASCOL baseline study was funded by the Research Council of Blekinge. MO
9
10 and ME was supported by an unrestricted grant from the Swedish Research Council (reference
11
12 number: 2019-02081).
13
14

15
16 **Competing Interests Statement:** None declared
17

18 **Ethics approval:** The baseline study was approved by the regional ethical review board at
19
20 Lund University (reference number: 2008/676). The first follow up study and the registry
21
22 data cross linkage was approved by the national ethical review board (reference number:
23
24 2019-00134).
25
26

27
28
29 **Data sharing statement:** The VASCOL research group will consider requests for using de-
30
31 identified data from the VASCOL study by external collaborators. Also, all requests must be
32
33 approved by the Sweden's national ethical review board.
34
35
36

37 38 39 **Licence statement**

40 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work
41
42 (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for
43
44 contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY
45
46 licence shall apply, and/or iii) in accordance with the terms applicable for US Federal
47
48 Government officers or employees acting as part of their official duties; on a worldwide,
49
50 perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and
51
52 where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the
53
54 Work in BMJ Open and any other BMJ products and to exploit all rights, as set out in our [licence](#).
55
56

57
58
59 The Submitting Author accepts and understands that any supply made under these terms is
60

1
2
3 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your
4
5 employer or a postgraduate student of an affiliated institution which is paying any applicable
6
7 article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes
8
9 to make the Work available on an Open Access basis (and intends to pay the relevant APC), the
10
11 terms of reuse of such Open Access shall be governed by a Creative Commons licence – details
12
13 of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our
14
15 licence referred to above.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol* 2017;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052 [published Online First: 2017/05/22]
2. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. *Clin Geriatr Med* 2009;25(4):563-77, vii. doi: 10.1016/j.cger.2009.07.007 [published Online First: 2009/12/01]
3. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 [published Online First: 2012/05/15]
4. Carter P, Lagan J, Fortune C, et al. Association of Cardiovascular Disease With Respiratory Disease. *J Am Coll Cardiol* 2019;73(17):2166-77. doi: 10.1016/j.jacc.2018.11.063 [published Online First: 2019/03/09]
5. Sandberg J, Ekstrom M, Borjesson M, et al. Underlying contributing conditions to breathlessness among middle-aged individuals in the general population: a cross-sectional study. *BMJ Open Respir Res* 2020;7(1) doi: 10.1136/bmjresp-2020-000643 [published Online First: 2020/09/27]
6. Zambroski CH, Moser DK, Bhat G, et al. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. *Eur J Cardiovasc Nurs* 2005;4(3):198-206. doi: 10.1016/j.ejcnurse.2005.03.010 [published Online First: 2005/05/27]
7. Laviolette L, Laveneziana P, Faculty ERSRS. Dyspnoea: a multidimensional and multidisciplinary approach. *Eur Respir J* 2014;43(6):1750-62. doi: 10.1183/09031936.00092613 [published Online First: 2014/02/15]
8. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *Eur Respir J* 2017;49(5) doi: 10.1183/13993003.02277-2016 [published Online First: 2017/05/27]
9. Smith AK, Currow DC, Abernethy AP, et al. Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. *J Am Geriatr Soc* 2016;64(10):2035-41. doi: 10.1111/jgs.14313 [published Online First: 2016/10/21]
10. Gronseth R, Vollmer WM, Hardie JA, et al. Predictors of dyspnoea prevalence: results from the BOLD study. *Eur Respir J* 2014;43(6):1610-20. doi: 10.1183/09031936.00036813 [published Online First: 2013/11/02]
11. Kochovska S, Chang S, Morgan DD, et al. Activities Forgone because of Chronic Breathlessness: A Cross-Sectional Population Prevalence Study. *Palliative Medicine Reports* 2020;1(1):166-70. doi: 10.1089/pmr.2020.0083
12. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. *Am J Respir Crit Care Med* 2012;185(4):435-52. doi: 10.1164/rccm.201111-2042ST [published Online First: 2012/02/18]
13. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. *Chest* 2002;121(5):1434-40. doi: 10.1378/chest.121.5.1434 [published Online First: 2002/05/15]
14. Currow DC, Dal Grande E, Ferreira D, et al. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax* 2017;72(12):1151-53. doi: 10.1136/thoraxjnl-2016-209908 [published Online First: 2017/03/31]

15. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet* 2007;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4 [published Online First: 2007/09/04]
16. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *Lancet* 2005;366(9500):1875-81. doi: 10.1016/S0140-6736(05)67632-5 [published Online First: 2005/11/29]
17. Heinrich J, Richter K, Frye C, et al. [European Community Respiratory Health Survey in Adults (ECRHS)]. *Pneumologie* 2002;56(5):297-303. doi: 10.1055/s-2002-30699 [published Online First: 2002/06/29]
18. Hutchinson A, Barclay-Klingbe N, Galvin K, et al. Living with breathlessness: a systematic literature review and qualitative synthesis. *Eur Respir J* 2018;51(2) doi: 10.1183/13993003.01477-2017 [published Online First: 2018/02/23]
19. Sundh J, Ekstrom M. Dyspnoea-12: a translation and linguistic validation study in a Swedish setting. *BMJ Open* 2017;7(5):e014490. doi: 10.1136/bmjopen-2016-014490 [published Online First: 2017/06/09]
20. Ekstrom M, Bornefalk H, Skold M, et al. Validation of the Swedish Multidimensional Dyspnea Profile (MDP) in outpatients with cardiorespiratory disease. *BMJ Open Respir Res* 2019;6(1):e000381. doi: 10.1136/bmjresp-2018-000381 [published Online First: 2019/11/05]
21. Ekstrom MP, Bornefalk H, Skold CM, et al. Minimal Clinically Important Differences and Feasibility of Dyspnea-12 and the Multidimensional Dyspnea Profile in Cardiorespiratory Disease. *J Pain Symptom Manage* 2020 doi: 10.1016/j.jpainsymman.2020.05.028 [published Online First: 2020/06/09]
22. Danielsson P, Olafsdottir IS, Benediktsdottir B, et al. The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden--the Burden of Obstructive Lung Disease (BOLD) study: cross-sectional population-based study. *Clin Respir J* 2012;6(2):120-7. doi: 10.1111/j.1752-699X.2011.00257.x [published Online First: 2011/06/10]
23. Ekstrom M, Chang S, Johnson MJ, et al. Low agreement between mMRC rated by patients and clinicians: implications for practice. *Eur Respir J* 2019;54(6) doi: 10.1183/13993003.01517-2019 [published Online First: 2019/10/19]
24. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. *Thorax* 2010;65(1):21-26. doi: 10.1136/thx.2009.118521
25. Hannon B, Dyck M, Pope A, et al. Modified Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer. *J Pain Symptom Manage* 2015;49(5):945-52. doi: 10.1016/j.jpainsymman.2014.10.013 [published Online First: 2014/12/20]
26. Al-shair K, Muellerova H, Yorke J, et al. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. *Health Qual Life Outcomes* 2012;10:100. doi: 10.1186/1477-7525-10-100 [published Online First: 2012/08/24]
27. Nowak C, Sievi NA, Clarenbach CF, et al. Accuracy of the Hospital Anxiety and Depression Scale for identifying depression in chronic obstructive pulmonary disease patients. *Pulm Med* 2014;2014:973858. doi: 10.1155/2014/973858 [published Online First: 2014/12/31]
28. Young J, Badgery-Parker T, Dobbins T, et al. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. *J Pain Symptom Manage* 2015;49(2):258-64. doi: 10.1016/j.jpainsymman.2014.06.006 [published Online First: 2014/07/06]
29. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. *J Manipulative Physiol Ther* 2004;27(1):26-35. doi: 10.1016/j.jmpt.2003.11.003 [published Online First: 2004/01/24]

FIGURE LEGENDS

Figure 1- Location of Blekinge in Sweden, Blekinge's municipalities and main cities.

Figure 2 - Flow chart of the recruitment for the VASCOL study

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1 - Location of Blekinge in Sweden, Blekinge's municipalities and main cities.

57x46mm (300 x 300 DPI)




Figure 2 - Flow chart of the recruitment for the VASCOL study

145x206mm (300 x 300 DPI)